Products - Ovarian cancer | Topic | NICE

Showing 13 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter
Status: PublishedRemove ‘Status: Published’ filter

Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]
Product type:
Guidance
Programme:
Technology appraisal guidance
Expected publication date:
20 February 2019
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA1007)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 September 2024
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA962)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 March 2024
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (TA946)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 January 2024
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy (TA908)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 July 2023
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 April 2022
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA673)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 February 2021
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) (TA560)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 February 2019
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 April 2016
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (TA353)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 August 2015
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 May 2013
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 May 2013
Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 May 2005
Published:
22 January 2003